PDF(Pubmed)
Abstract：
Ribavirin ampoule formulation remains a major challenge in managing Lassa fever disease. Lassa fever is an endemic viral hemorrhagic fever in the West Africa subregion, which has high-dose ribavirin as the standard of care. The high-dose therapy required makes the 200 mg/ml ampoule dosing of ribavirin a daunting task to administer, especially during disease outbreaks. This commentary highlights the challenges and makes a passionate call for vial dosage adjustment to fit the high-dose requirement of Lassa fever disease.
摘要：
利巴韦林安瓿制剂仍然是管理拉沙热疾病的主要挑战。拉沙热是西非次区域的地方性病毒性出血热,其中以高剂量利巴韦林为护理标准。所需的高剂量治疗使200mg/ml安瓿剂量的利巴韦林成为一项艰巨的任务，尤其是在疾病爆发期间。这篇评论强调了挑战，并热情地呼吁调整小瓶剂量以适应拉沙热疾病的高剂量要求。
